Related Experiment Video
Updated: Jun 23, 2025
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
New Insights Into the Treatment of Hyperlipidemia: Pharmacological Updates and Emerging Treatments
Seema Abbasi1, Adnan Khan2, Muhammad W Choudhry3
1Internal Medicine, Sutter Health, Stockton, USA.
Insights
Hyperlipidemia management is evolving, with established statins and novel therapies like PCSK9 inhibitors offering improved cardiovascular outcomes. Research continues into emerging treatments for better lipid control.
Area of Science:
- Cardiology
- Metabolic Disorders
- Pharmacology
Background:
- Cardiovascular diseases (CVDs) are a leading global cause of death.
- Hyperlipidemia, characterized by abnormal blood lipid levels, is a major risk factor for atherosclerosis and CVDs.
- Current treatments include lifestyle changes and medications like statins.
Purpose of the Study:
- To review the pathophysiology of hyperlipidemia.
- To explore current and emerging management strategies and pharmacotherapies.
- To highlight the clinical efficacy and safety of various lipid-lowering treatments.
Main Methods:
- Literature review of established and novel pharmacotherapies for hyperlipidemia.
- Analysis of mechanisms of action, clinical efficacy, and safety profiles.
- Examination of emerging therapies in clinical trials.
Main Results:
- Established therapies (statins, fibrates, ezetimibe) and novel agents (PCSK9 inhibitors, inclisiran, lomitapide, bempedoic acid) demonstrate varying efficacy and safety.
- Emerging therapies (ApoC-III inhibitors, DGAT2 inhibitors, ACAT2 Inhibitors, LPL gene therapies) show potential for improved lipid homeostasis.
- The review synthesizes current knowledge on hyperlipidemia pharmacotherapy.
Conclusions:
- The management of hyperlipidemia is advancing with a range of therapeutic options.
- Novel and emerging therapies offer promising avenues for enhancing lipid management and reducing cardiovascular risk.
- Continued research is crucial for optimizing treatment strategies and improving patient outcomes.
Abstract:
Cardiovascular diseases are the leading causes of global mortality and morbidity. Hyperlipidemia is a significant risk factor for atherosclerosis and subsequent cardiovascular diseases. Hyperlipidemia is characterized by imbalances in blood cholesterol levels, particularly elevated low-density lipoprotein cholesterol and triglycerides, and is influenced by genetic and environmental factors. Current management consists of lifestyle modifications and pharmacological interventions most commonly consisting of statins. This review paper explores pathophysiology, management strategies, and pharmacotherapies including commonly used well-established medications including statins, fibrates, and ezetimibe, exciting novel therapies including proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, and RNA interference therapies (inclisiran), lomitapide, and bempedoic acid, highlighting their mechanisms of action, clinical efficacy, and safety profiles. Additionally, emerging therapies under clinical trials including ApoC-III inhibitors, DGAT2 inhibitors, ACAT2 Inhibitors, and LPL gene therapies are examined for their potential to improve lipid homeostasis and cardiovascular outcomes. The evolving landscape of hyperlipidemia management underscores the importance of continued research into both established therapies and promising new candidates, offering hope for more effective treatment strategies in the future.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers